OverviewSuggest Edit

AlloVir (formerly ViraCyte) is a company that develops and delivers transformative cell therapies for patients suffering from life-threatening virus-associated diseases. It focuses on the clinical development of novel cell therapies designed to restore natural T-cell immunity against devastating virus-associated diseases in immunocompromised patients, including stem cell and organ transplant recipients.

HQHouston, US

Latest Updates

Employees (est.) (Apr 2020)22

Key People/Management at AlloVir

David Hallal

David Hallal

Ann Leen

Ann Leen

Chief Scientific Officer
Vikas Sinha

Vikas Sinha

President, CFO
Agustin Melian

Agustin Melian

Chief Medical Officer, Head of Global Medical Sciences
Jeroen van Beek

Jeroen van Beek

Chief Commercial Officer
Juan Vera

Juan Vera

Chief Product Development Officer
Show more

AlloVir Office Locations

AlloVir has an office in Houston
Houston, US (HQ)
2925 Richmond Ave
Show all (1)

AlloVir Financials and Metrics

Summary Metrics

Founding Date


AlloVir total Funding

$159 m

AlloVir latest funding size

$120 m

Time since last funding

a year ago

AlloVir investors

AlloVir's latest funding round in May 2019 was reported to be $120 m. In total, AlloVir has raised $159 m
Show all financial metrics

AlloVir Online and Social Media Presence

Embed Graph

AlloVir Blogs

European Medicines Agency Grants Orphan Drug Designation to AlloVir’s Viralym-M, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T-Cell Therapy

AlloVir, a late-clinical stage allogeneic T-cell immunotherapy company, today announced it has been granted Orphan Drug Designation from the European Medicines Agency (EMA) for Viralym-M (ALVR105) as a potential treatment of viral diseases and infections in patients undergoing hematopoietic stem…

AlloVir Expands Its Research Collaboration with Baylor College of Medicine to Discover and Develop Allogeneic, Off-the-Shelf, Virus-Specific T-Cell Therapies for COVID-19

AlloVir, a late-clinical stage T-cell immunotherapy company, today announced the expansion of its research and development collaboration with Baylor College of Medicine to include the discovery and development of allogeneic, off-the-shelf, virus specific T-cell therapies to combat SARS-CoV-2, th…

Phase I Study of “Off-The-Shelf” Virus-Specific T Cells Published in BLOOD ADVANCES

Research published in the journal BLOOD ADVANCES established the feasibility of using a small bank of third-party cell lines generated from carefully chosen donors to provide virus-specific T-cell therapy to a large number of patients. The data show coverage of more than 95 percent of patients w…

AlloVir Announces Viralym-M Granted Regenerative Medicine Advanced Therapy (RMAT) Designation

AlloVir, a late-clinical stage allogeneic T-cell therapy company, today announced that it has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) for Viralym-M (ALVR105), its lead allogeneic, off-the-shelf, multi-virus specific T-ce…

AlloVir Frequently Asked Questions

  • When was AlloVir founded?

    AlloVir was founded in 2013.

  • Who are AlloVir key executives?

    AlloVir's key executives are David Hallal, Ann Leen and Vikas Sinha.

  • How many employees does AlloVir have?

    AlloVir has 22 employees.

  • Who are AlloVir competitors?

    Competitors of AlloVir include NorInvent, Glycostem and Elpiscience Biopharmaceuticals.

  • Where is AlloVir headquarters?

    AlloVir headquarters is located at 2925 Richmond Ave, Houston.

  • Where are AlloVir offices?

    AlloVir has an office in Houston.

  • How many offices does AlloVir have?

    AlloVir has 1 office.